HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial.

AbstractBACKGROUND:
Nitrous oxide (N2O) has been reported to increase the risk of postoperative nausea and vomiting (PONV) in a dose-dependent manner. We investigated the effect of adding N2O at the end of isoflurane inhalational anesthesia on the recovery and incidence of PONV. Our hypothesis was that N2O would reduce the time to early recovery without increasing the incidence of PONV.
METHODS:
After obtaining ethics committee approval and written informed consent, 100 women at American Society of Anesthesiologists physical status I-III and scheduled for laparoscopic-assisted vaginal hysterectomy were randomized into two groups (G) according to the carrier gas: GO2 (air in 30% oxygen) and GN2O (the same mixture until the last 30 min of surgery, when 70% N2O in 30% oxygen was used). No PONV prophylaxis was given. Anesthesia was induced with thiopental 5 mg·kg-1, vecuronium 0.1 mg·kg-1, and fentanyl 1-2 μg·kg-1 iv and maintained with isoflurane. Indicators of early recovery (time to extubation, eye opening, following commands, orientation) were assessed by an anesthesiologist unaware of the group assignment. The incidence and severity of PONV was measured at two and 24 hr postoperatively.
RESULTS:
Altogether, 82 participants completed the study (42 in GO2, 40 in GN2O) and were analyzed. The mean (SD) time of N2O administration in GN2O patients was 27.1 (10.1) min. The mean (SD) time to extubation was faster in GN2O patients [5.4 (2.9) min] than in GO2 patients [7.5 (3.7) min] (mean difference, 2.0 min; 95% confidence interval [CI], 0.6 to 3.4, P = 0.009). The ability to open eyes, follow commands, and being oriented were all faster in GN2O patients than in GO2 patients (differences of 3.9 min, 95% CI, 1.6 to 6.1, P = 0.001; 3.4 min, 95% CI, 1.0 to 5.7, P = 0.006; 3.8 min, 95% CI, 0.9 to 6.7, P = 0.010, respectively). The incidence of PONV was not different between the groups, but the rescue antiemetic was required less often in the GN2O patients (mean difference in metoclopramide dose between the GN2O and GO2 groups, 5.1 mg; 95% CI, 0.8 to 9.4, P = 0.019).
CONCLUSIONS:
Adding N2O during the last 30 min of an isoflurane-based inhalational anesthetic reduced the time to extubation, eye opening, and orientation.
AuthorsBoris Mraovic, Tatjana Simurina, Tong J Gan
JournalCanadian journal of anaesthesia = Journal canadien d'anesthesie (Can J Anaesth) Vol. 65 Issue 2 Pg. 162-169 (02 2018) ISSN: 1496-8975 [Electronic] United States
Vernacular TitleL’ajout de protoxyde d’azote à la fin d’une anesthésie à l’isoflurane accélère la récupération précoce sans augmenter le risque de nausées et vomissements postopératoires : une étude clinique randomisée.
PMID29150782 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anesthetics, Inhalation
  • Antiemetics
  • Vecuronium Bromide
  • Isoflurane
  • Thiopental
  • Nitrous Oxide
  • Fentanyl
Topics
  • Adult
  • Anesthesia Recovery Period
  • Anesthetics, Inhalation (administration & dosage, adverse effects)
  • Antiemetics (administration & dosage)
  • Dose-Response Relationship, Drug
  • Female
  • Fentanyl (administration & dosage)
  • Humans
  • Hysterectomy, Vaginal (methods)
  • Incidence
  • Isoflurane (administration & dosage, adverse effects)
  • Laparoscopy (methods)
  • Middle Aged
  • Nitrous Oxide (administration & dosage, adverse effects)
  • Postoperative Nausea and Vomiting (epidemiology)
  • Thiopental (administration & dosage)
  • Vecuronium Bromide (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: